Ontology highlight
ABSTRACT:
SUBMITTER: O'Donnell EK
PROVIDER: S-EPMC6074026 | biostudies-literature | 2018 Jul
REPOSITORIES: biostudies-literature
O'Donnell Elizabeth K EK Laubach Jacob P JP Yee Andrew J AJ Chen Tianqi T Huff Carol Ann CA Basile Frank G FG Wade Philip M PM Paba-Prada Claudia E CE Ghobrial Irene M IM Schlossman Robert L RL Burke Jill N JN Harrington Cynthia C CC Lively Kathleen J KJ Lyons Hannah F HF Munshi Nikhil C NC Anderson Kenneth C KC Trippa Lorenzo L Richardson Paul G PG Raje Noopur S NS
British journal of haematology 20180508 2
We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m<sup>2</sup> weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib ...[more]